HEALTHJun 3 · 23:01 UTCTHE GUARDIAN WORLDAnna Bawden Health and social affairs correspondent

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

NHS England approved Elahere, the first new drug for chemotherapy-resistant ovarian cancer in over 20 years, offering life-prolonging treatment to hundreds of women. Ovarian cancer affects over 300,000 women annually, with most diagnosed at advanced stages.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

ElaheretopicNHS Englandorganizationovarian cancertopicchemotherapy-resistant ovarian cancertopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 3 · 23:17 UTC
Hope for thousands of ovarian cancer patients as new drug which slashes risk of death by a third is made available on the NHS
HEALTHApr 10 · 19:55 UTC
Repurposed drug may extend survival in aggressive ovarian cancer, trial shows
HEALTHApr 12 · 15:02 UTC
GSK reports promising early results in ovarian and womb cancer drug trial
HEALTHJun 3 · 23:34 UTC
Breakthrough ovarian cancer drug offers patients more time and better quality of life
HEALTHMay 11 · 09:05 UTC
Common cholesterol drug could help treat ovarian cancer, promising new research suggests
HEALTHMay 11 · 09:13 UTC
Common cholesterol drug could help treat ovarian cancer, promising new research suggests